 Galera Therapeutics, Inc. GRTX, a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that full results from the 223-patient, randomized, double-blind Phase 2b clinical trial of lead candidate GC4419 avasopasem manganese in patients with locally advanced head and neck cancer have been published in the Journal of Clinical Oncology, a journal of the American Society of Clinical Oncology ASCO. 